Physician profile
Michael A Reed
NPI 1558411553
$548.79
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $92.81 · 2022: $28.98.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $177.88 | 2019 | |
| Therapeuticsmd, INC. | $135.86 | 2019 | |
| Abbvie INC. | $104.30 | 2019-2020 | |
| Intuitive Surgical, INC. | $28.98 | 2022 | |
| Mallinckrodt Enterprises LLC | $25.12 | 2019 | |
| Mallinckrodt Hospital Products INC. | $19.35 | 2020 | |
| Merck Sharp & Dohme LLC | $19.14 | 2020 | |
| Roche Diagnostics Corporation | $15.07 | 2019 | |
| Allergan, INC. | $12.07 | 2019 | |
| Zyla Life Sciences, INC. | $11.02 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.